Enterobacteriaceae Infections
2
Pipeline Programs
7
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 program1
Fecal Microbiota TransplantationPhase 11 trial
Active Trials
Allergy TherapeuticsUK - West Sussex
1 programCommunity-associated Highly-Resistant EnterobacteralesN/A1 trial
Active Trials
MSDIreland - Ballydine
1 programRisk factors for infections due to ESBL+ EnterobacteriaceaeN/A1 trial
Active Trials
Sharp TherapeuticsPA - Pittsburgh
1 programRisk factors for infections due to ESBL+ EnterobacteriaceaeN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Angeles TherapeuticsFecal Microbiota Transplantation
Allergy TherapeuticsCommunity-associated Highly-Resistant Enterobacterales
MSDRisk factors for infections due to ESBL+ Enterobacteriaceae
Clinical Trials (3)
Total enrollment: 2,985 patients across 3 trials
Pilot Study Using Oral Capsule FMT to Decolonize GI CRE
Start: Jun 2019Est. completion: Sep 20190
Phase 1Withdrawn
Community-associated Highly-Resistant Enterobacterales
Start: May 2019Est. completion: Dec 20242,172 patients
N/ACompleted
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
Start: Oct 2006Est. completion: Nov 2006813 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
7 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.